{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:57:28Z","timestamp":1790035048664,"version":"4.0.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","award":["70112835"],"award-info":[{"award-number":["70112835"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","award":["70113510"],"award-info":[{"award-number":["70113510"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","award":["70114428"],"award-info":[{"award-number":["70114428"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018931","name":"AIO-Studien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018931","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health at Charit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012634","name":"Novocure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.annonc.2025.12.011","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T16:57:08Z","timestamp":1767113828000},"page":"686-700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["PET\/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7452-7129","authenticated-orcid":false,"given":"N.","family":"Frost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Joosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0761-641X","authenticated-orcid":false,"given":"J.","family":"Franzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9698-9559","authenticated-orcid":false,"given":"M.","family":"Wiesweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rasokat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-1687","authenticated-orcid":false,"given":"J.","family":"Kulhavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Reinmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Groh\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Roeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5280-6052","authenticated-orcid":false,"given":"A.","family":"Rittmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Heinzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4844-4087","authenticated-orcid":false,"given":"M.","family":"Wermke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9261-7504","authenticated-orcid":false,"given":"C.","family":"Wesseler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-8980","authenticated-orcid":false,"given":"P.","family":"Christopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kauffmann-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Althoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bleckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0932-2471","authenticated-orcid":false,"given":"M.","family":"Collienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Berezucki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2579-0171","authenticated-orcid":false,"given":"T.","family":"Overbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kropf-Sanchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Griesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0404-7741","authenticated-orcid":false,"given":"M.","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2166-3394","authenticated-orcid":false,"given":"M.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-7886","authenticated-orcid":false,"given":"C.","family":"Furth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4442-7116","authenticated-orcid":false,"given":"P.","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-4462","authenticated-orcid":false,"given":"M.","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.annonc.2025.12.011_bib1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.annonc.2025.12.011_bib2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"10183","key":"10.1016\/j.annonc.2025.12.011_bib3","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"10274","key":"10.1016\/j.annonc.2025.12.011_bib4","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.annonc.2025.12.011_bib5","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.annonc.2025.12.011_bib6","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.annonc.2025.12.011_bib7","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.annonc.2025.12.011_bib8","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.annonc.2025.12.011_bib9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2025.12.011_bib10","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.annonc.2025.12.011_bib11","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.annonc.2025.12.011_bib12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2025.12.011_bib13","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.annonc.2025.12.011_bib14","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10212","key":"10.1016\/j.annonc.2025.12.011_bib15","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"33","key":"10.1016\/j.annonc.2025.12.011_bib16","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1200\/JCO.20.00131","article-title":"Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153","volume":"38","author":"Waterhouse","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2025.12.011_bib17","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer","volume":"9","author":"Sun","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2025.12.011_bib18","article-title":"Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study","volume":"43","author":"Rousseau","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.annonc.2025.12.011_bib19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","article-title":"Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer","volume":"3","author":"Liu","year":"2022","journal-title":"Nature Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2025.12.011_bib20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.annonc.2025.12.011_bib21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.12.011_bib22","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC","volume":"16","author":"Jassem","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.12.011_bib23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","article-title":"Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050","volume":"9","author":"Chen","year":"2023","journal-title":"JAMA Oncol"},{"issue":"21","key":"10.1016\/j.annonc.2025.12.011_bib24","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.12.011_bib25","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.12.011_bib26","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2025.12.011_bib27","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/annonc\/mdy330","article-title":"FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma","volume":"29","author":"Tan","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2025.12.011_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002955","article-title":"PET\/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma","volume":"9","author":"Gibney","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.12.011_bib29","article-title":"A phase II study of biomarker-driven early discontinuation of anti\u2013PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192","volume":"40","author":"Gibney","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.12.011_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005921","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors","volume":"11","author":"Kluger","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2025.12.011_bib31","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"O","year":"2016","journal-title":"Radiology"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.12.011_bib32","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.annonc.2025.12.011_bib33","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.12.011_bib34","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.annonc.2025.12.011_bib35","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1200\/JCO.23.00282","article-title":"Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO Living Guideline, Version 2023.1","volume":"41","author":"Singh","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.12.011_bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.annonc.2025.12.011_bib37","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1158\/1078-0432.CCR-23-1207","article-title":"Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non\u2013small cell lung cancer","volume":"29","author":"Thummalapalli","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.annonc.2025.12.011_bib38","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.12.011_bib39","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.12.011_bib40","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1093\/annonc\/mdx414","article-title":"Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy","volume":"28","author":"McCoach","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.12.011_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115119","article-title":"Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: a pooled analysis in 935 patients","volume":"214","author":"Robert","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2025.12.011_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104016","article-title":"A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: the OTHERS study","volume":"187","author":"Bogani","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.annonc.2025.12.011_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102791","article-title":"Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer","volume":"129","author":"Marinello","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/j.annonc.2025.12.011_bib44","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.annonc.2025.03.019","article-title":"Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"36","author":"Valenza","year":"2025","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.12.011_bib45","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/s41591-023-02226-6","article-title":"A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer","volume":"29","author":"Assaf","year":"2023","journal-title":"Nat Med"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2025.12.011_bib46","article-title":"101P Circulating tumor DNA minimal residual disease predicts the risk of progression after long-term response to first-line immunotherapy in advanced NSCLC","volume":"35","author":"Wu","year":"2024","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.12.011_bib47","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"issue":"10422","key":"10.1016\/j.annonc.2025.12.011_bib49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.12.011_bib50","doi-asserted-by":"crossref","first-page":"9068","DOI":"10.1200\/JCO.2023.41.16_suppl.9068","article-title":"Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial","volume":"41","author":"Zalcman","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2025.12.011_bib51","article-title":"1258MO Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: results of the pre-planned interim analysis of the NVALT-30 clinical trial","volume":"35","author":"van den Heuvel","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.12.011_bib52","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2025.12.011_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update","volume":"12","author":"Fletcher","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2025.12.011_bib54","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.12.011_bib55","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0643","article-title":"Association of disease progression with health-related quality of life among adults with breast, lung, pancreatic, and colorectal Cancer","volume":"3","author":"Marschner","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.annonc.2025.12.011_bib56","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2024.07.014","article-title":"Second primary lung cancer \u2013 an emerging issue in lung cancer survivors","volume":"19","author":"Jensen","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.12.011_bib57","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/s41571-025-01061-7","article-title":"Treatment of NSCLC after chemoimmunotherapy \u2013 are we making headway?","volume":"22","author":"Reck","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.12.011_bib58","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"7870","key":"10.1016\/j.annonc.2025.12.011_bib59","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41586-021-03752-4","article-title":"Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers","volume":"596","author":"Caushi","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.annonc.2025.12.011_bib60","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.annonc.2025.12.011_bib61","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1038\/s41467-023-40745-5","article-title":"Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype","volume":"14","author":"Hiltbrunner","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.annonc.2025.12.011_bib62","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","article-title":"Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels","volume":"8","author":"Ricciuti","year":"2022","journal-title":"JAMA Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.12.011_bib63","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","article-title":"NRG-LU002: Randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC)","volume":"42","author":"Iyengar","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.12.011_bib64","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41392-025-02460-z","article-title":"Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1\/L1 therapy (BOOSTER): a randomized phase 2 trial","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.annonc.2025.12.011_bib65","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.29874","article-title":"Updated analysis of complication rates associated with invasive diagnostic procedures after lung cancer screening","volume":"3","author":"Zhao","year":"2020","journal-title":"JAMA Netw Open"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342506329X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342506329X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:16:01Z","timestamp":1784704561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342506329X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S092375342506329X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.12.011","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET\/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}